ChemPartner(SZ:300149)2025-04-30 10:34Group 1: Financial Performance - In 2024, the company achieved a revenue of 970 million CNY, a year-on-year decrease of 14.77% due to challenges in the innovative drug industry and intense market competition [2][3] - The net profit attributable to shareholders was -226 million CNY, a year-on-year improvement of 75.30% due to reduced asset impairment provisions [3] - In Q1 2025, the company reported a revenue of 261 million CNY, a year-on-year increase of 11.37%, and a net profit of 6.64 million CNY, marking a return to profitability [3] Group 2: Strategic Planning - The company is upgrading its comprehensive service strategy to differentiate itself from competitors, leveraging 20 years of CRO experience to provide integrated solutions from target identification to IND [4] - AI technology is being integrated into drug development processes to enhance operational efficiency and market competitiveness, with ongoing deployment of DeepSeek technology [4] - The company aims to strengthen its domestic and international business development (BD) systems, focusing on major clients domestically and expanding its European team [4] Group 3: Market and Business Development - The company plans to increase its domestic market share, currently below 20%, by enhancing comprehensive service orders and local channel development [5] - The global market, including domestic demand, is showing signs of recovery in 2025, prompting the company to intensify its domestic market development efforts [9] - The company has seen an increase in orders in the ADC and peptide sectors, with strategic expansions into new drug platforms [8] Group 4: Technological Advancements - The company has developed comprehensive capabilities in new molecular and modality areas, including ADC, peptides, and PROTAC, with over 2,000 linker-payload designs completed [7][11] - The company has established a complete one-stop service platform for ADC/XDC drug development, covering all stages from target validation to clinical application [10] - Continuous investment in new modalities and technologies is planned to maintain competitive advantages in drug development [11] Group 5: Collaboration and Partnerships - The company has maintained a long-term partnership with Eli Lilly, successfully passing their site audit, and continues to collaborate with various subsidiaries [11] - Strategic collaborations with universities enhance the company's technical reserves and support future order acquisition [12]